PITTSBURGH, May 13, 2026
Renerva, Inc. announced the successful first-in-human implantation of its investigational PNM-CAP™ device, marking a major milestone in the company’s effort to develop innovative solutions for chronic neuroma pain and peripheral nerve injuries. The procedure was performed at The Ohio State University Wexner Medical Center as part of Renerva’s first-in-human clinical study evaluating the safety and effectiveness of the nerve capping technology in patients suffering from severe neuropathic pain.
The implantation represents Renerva’s transition into a clinical-stage medical device company and positions the organization for future regulatory clearance and commercial expansion within the rapidly growing nerve repair and pain management sector. Company executives described the milestone as a critical advancement toward addressing a significant unmet medical need affecting amputees and patients with severe nerve injuries.
PNM-CAP Designed to Prevent Chronic Neuroma Pain
Renerva’s investigational PNM-CAP™ device was specifically developed to inhibit disorganized nerve regrowth, commonly known as neuroma formation, following nerve injury or amputation procedures. Neuromas are widely recognized as one of the leading causes of chronic neuropathic pain in amputees and often contribute to reduced mobility, diminished quality of life, and long-term opioid dependency.
The device is intended for cases in which functional recovery of a severed nerve is not achievable or clinically necessary. By capping the injured nerve ending, Renerva aims to prevent abnormal nerve regeneration that frequently results in severe and persistent pain. Company leadership stated that the technology may help establish a new standard of care for nerve management procedures in amputee patients and other individuals experiencing debilitating neuropathic conditions.
Advertisement
According to Renerva CEO Lorenzo Soletti, the company rapidly advanced from receiving FDA Investigational Device Exemption approval to performing its first implantation within only a few months, highlighting strong operational execution and growing clinical momentum. The company stated it is actively preparing for FDA market clearance and commercial launch in the near future.
Clinical Study Evaluates Pain Reduction and Quality of Life
The prospective pilot study is evaluating patients undergoing surgical nerve management procedures for chronic neuropathic pain. Primary clinical endpoints include measuring reductions in pain severity, opioid consumption, and overall improvements in patient quality of life, outcomes that align closely with value-based healthcare priorities and long-term rehabilitation goals.
The first implantation procedure was led by Amy M. Moore, MD, Interim Dean of The Ohio State University College of Medicine and Chair of the Department of Plastic and Reconstructive Surgery. Dr. Moore noted that the PNM-CAP device integrated smoothly into standard surgical workflows and may provide physicians with a practical strategy for preventing neuroma formation in high-risk patients.
Clinical investigators emphasized that current treatment options for chronic neuroma pain remain limited and often fail to provide durable symptom relief. Persistent neuropathic pain can interfere with prosthetic use, rehabilitation outcomes, and psychological well-being, creating significant long-term healthcare challenges for patients and providers alike.
Device Innovation Addresses Opioid and Amputation Challenges
Medical experts involved in the study highlighted the broader healthcare significance of the technology, particularly given the large number of extremity amputations performed annually in the United States. Researchers estimate that approximately 500,000 new extremity amputations occur each year, creating a substantial population at risk for chronic nerve pain and opioid dependence.
Specialists believe that successful prevention of neuroma formation could improve prosthetic fitting outcomes, increase patient mobility, and reduce reliance on long-term pain medications. Reducing chronic opioid exposure has become an especially important goal as healthcare systems continue addressing opioid-related complications and addiction risks.
Renerva stated that the PNM-CAP device reflects the growing trend toward targeted nerve repair technologies and regenerative surgical solutions within the MedTech sector. As innovation in peripheral nerve management accelerates, the company believes its nerve capping platform could play an important role in improving long-term outcomes for patients suffering from severe nerve injuries and chronic neuropathic pain conditions
Source: Renerva press release
